Sympathetic axonogenesis promotes adenoid cystic carcinoma progression
- PMID: 40272482
- PMCID: PMC12020745
- DOI: 10.1084/jem.20242250
Sympathetic axonogenesis promotes adenoid cystic carcinoma progression
Abstract
Nerves are integral to the adenoid cystic carcinoma (ACC) microenvironment. The strong association of ACC with perineural invasion (PNI) is considered a hallmark of this disease. In human salivary ACC, we identify intratumoral, small-caliber, disorganized sympathetic nerves not observed in other salivary neoplasms. Norepinephrine or sympathetic ganglia explants enhance ACC proliferation in vitro. Two novel orthotopic ACC patient-derived xenograft (PDX) models recapitulate ACC morphology and demonstrate sympathetic innervation. Pharmacologic or surgical blockade of sympathetic nerves decreases ACC PDX growth. Bulk RNA sequencing of salivary ACC reveals correlations between noradrenergic nerve development signatures and worse patient survival. Metastatic ACC foci exhibit lower nerve signature gene expression levels than primary ACC. Sympathetic innervation in ACC is distinct from PNI and reflects tumor axonogenesis driven by noradrenergic neural development programs. These programs support ACC progression, are associated with poor prognosis, and may be inhibited as a therapeutic strategy.
© 2025 Chen et al.
Conflict of interest statement
Disclosures: A.L. Ho reported personal fees from Physician Education Resources and Takeda; grants from Daichi Sankyo; other from Lepu Biopharma and Hookipa; grants from Rgenta Therapeutics and Remix Therapeutics; personal fees from Nested Therapeutics, Exelixis, Eisai, Affyimmune, and Kura Oncology; grants from Merck; personal fees from ExpertConnect, Elevar Therapeutics, and Prelude Therapeutics; grants from Verastem, Bayer, Genentech, Kura Oncology, Eisai, and BMS; personal fees from Remix Therapeutics and Rgenta Therapeutics; grants from Astellas, Novartis, and AstraZeneca; and personal fees from Inhibrx outside the submitted work. In addition, A.L. Ho had a patent on lesional dosimetry methods for tailoring targeted radiotherapy in cancer, serial no. 63/193700, filed 5/27/2021, pending. No other disclosures were reported.
References
-
- Amit, M., Binenbaum Y., Trejo-Leider L., Sharma K., Ramer N., Ramer I., Agbetoba A., Miles B., Yang X., Lei D., et al. 2015. International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck. 37:1038–1045. 10.1002/hed.23710 - DOI - PubMed
-
- Amit, M., Anastasaki C., Dantzer C., Demir I.E., Deneen B., Dixon K.O., Egeblad M., Gibson E.M., Hervey-Jumper S.L., Hondermarck H., et al. 2024. Next Directions in the Neuroscience of Cancers Arising outside the CNS. Cancer Discov. 14:669–673. 10.1158/2159-8290.CD-23-1495 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical